Produção Nacional
Effectiveness of Primary and Booster COVID-19 mRNA Vaccination against Omicron Variant SARS-CoV-2 Infection in People with a Prior SARS-CoV-2 Infection
2022; Cold Spring Harbor Laboratory; Linguagem: Inglês
10.1101/2022.04.19.22274056
AutoresMargaret L. Lind, Alexander J. Robertson, Julio Silva, Frederick Warner, Andreas Coppi, Nathan D. Price, Chelsea Duckwall, Peri Sosensky, Eréndira C. Di Giuseppe, Ryan Borg, Mariam O. Fofana, Otávio T. Ranzani, Natalie E. Dean, Jason R. Andrews, Júlio Croda, Akiko Iwasaki, Derek A. T. Cummings, Albert I. Ko, Matt D. T. Hitchings, Wade L. Schulz,
Tópico(s)Animal Virus Infections Studies
ResumoAbstract Background The benefit of vaccination in people who experienced a prior SARS-CoV-2 infection remains unclear. Objective To estimate the effectiveness of primary (two-dose) and booster (third dose) vaccination against Omicron infection among people with a prior documented infection. Design Test-negative case-control study. Setting Yale New Haven Health System facilities. Participants Vaccine eligible people who received SARS-CoV-2 RT-PCR testing between November 1, 2021, and January 31, 2022. Measurements We conducted two analyses, each with an outcome of Omicron BA.1 infection (S-gene target failure defined) and each stratified by prior SARS-CoV-2 infection status. We estimated the effectiveness of primary and booster vaccination. To test whether booster vaccination reduced the risk of infection beyond that of the primary series, we compared the odds among boosted and booster eligible people. Results Overall, 10,676 cases and 119,397 controls were included (6.1% and 7.8% occurred following a prior infection, respectively). The effectiveness of primary vaccination 14-149 days after 2 nd dose was 36.1% (CI, 7.1% to 56.1%) for people with and 28.5% (CI, 20.0% to 36.2%) without prior infection. The odds ratio comparing boosted and booster eligible people with prior infection was 0.83 (CI, 0.56 to 1.23), whereas the odds ratio comparing boosted and booster eligible people without prior infection was 0.51 (CI, 0.46 to 0.56). Limitations Misclassification, residual confounding, reliance on TaqPath assay analyzed samples. Conclusion While primary vaccination provided protection against BA.1 infection among people with and without prior infection, booster vaccination was only associated with additional protection in people without prior infection. These findings support primary vaccination in people regardless of prior infection status but suggest that infection history should be considered when evaluating the need for booster vaccination. Primary Funding Source Beatrice Kleinberg Neuwirth and Sendas Family Funds, Merck and Co through their Merck Investigator Studies Program, and the Yale Schools of Public Health and Medicine.
Referência(s)